...in China, including Hong Kong and Macau, and Taiwan to hypertension drug aliskiren. Manufacturing of aliskiren...
...treat hypertension. Aliskiren, a renin inhibitor, is marketed as Tekturna in the U.S. and as Rasilez...
...Incline Village, Nev. Lee's Pharmaceutical Holdings Ltd. (HKSE:950), Hong Kong, China Business: Cardiovascular, Cancer, Neurology Chris Lieu aliskiren Rasilez Tekturna Zingo ZKAB001 Lee's...

...the Novartis-MIT group built an end-to-end process for the pharma’s high blood pressure drug Rasilez aliskiren...

...Novartis granted newly launched PDL subsidiary, Noden Pharma DAC, exclusive, worldwide commercialization rights to aliskiren to...
...an aliskiren generic. Aliskiren, a renin inhibitor, is marketed as Tekturna in the U.S. and Rasilez...

...don't translate well." While Novartis' approach with LCZ696 - and its other compounds serelaxin and aliskiren...
...for heart failure. The compound is partnered with Endo International plc and GlaxoSmithKline plc . Aliskiren...
...for treatment of hypertension in the U.S. as Tekturna , and in the EU as Rasilez...

...don’t translate well.” While Novartis’ approach with LCZ696 - and its other compounds serelaxin and aliskiren...
...for heart failure. The compound is partnered with Endo International plc and GlaxoSmithKline plc . Aliskiren...
...for treatment of hypertension in the U.S. as Tekturna , and in the EU as Rasilez...

...who need more intensive therapy. Novartis markets aliskiren as Tekturna in the U.S. and as Rasilez...
...price of $3,000 per year ($250 per month). The bigger picture Along with serelaxin and aliskiren...
...chronic heart failure. The Phase III ATMOSPHERE study is testing aliskiren monotherapy, enalapril therapy, and aliskiren...

...April, PRAC supported the conclusions of an EMA review, which concluded in February 2012 that aliskiren...
...hypertension drug Rasilez / Tekturna aliskiren from Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) and other aliskiren-containing...

...evaluable patients in the double-blind, international Phase III AQUARIUS trial showed that once-daily 300 mg aliskiren...
...vs. placebo. Specifically, aliskiren reduced PAV by 0.33% vs. a 0.11% increase for placebo (p=0.08). Aliskiren...
...hypertension. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Aliskiren ( Rasilez , Tekturna ) ( SPP100...

...diabetes or moderate to severe renal impairment (glomerular filtration rate <60 mL/min/1.73 m2) who take aliskiren-containing...
...hypertension drug Rasilez / Tekturna aliskiren from Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) and other aliskiren-containing...
...ACE) inhibitors or angiotensin-receptor blockers (ARB). In April 2012, Novartis updated the label for Tekturna aliskiren...

...diabetes or moderate to severe renal impairment (glomerular filtration rate <60 mL/min/1.73 m2) who take aliskiren-containing...
...hypertension drug Rasilez / Tekturna aliskiren from Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) and other aliskiren-containing...
...ACE) inhibitors or angiotensin-receptor blockers (ARB). In April 2012, Novartis updated the label for Tekturna aliskiren...